<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867187</url>
  </required_header>
  <id_info>
    <org_study_id>21CH035</org_study_id>
    <secondary_id>2021-A00720-41</secondary_id>
    <nct_id>NCT04867187</nct_id>
  </id_info>
  <brief_title>rTMS Efficacy Coupled With Mirror Therapy</brief_title>
  <acronym>STIRM</acronym>
  <official_title>Clinical Study of Repetitive Transcranial Magnetic Stimulation (RTMS) Efficacy Coupled With Mirror Therapy for Neuropathic Pain Relief</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuropathic pain is particularly difficult to treat with classic first-line drugs.&#xD;
      Neuromodulation techniques using repetitive transcranial magnetic stimulation (rTMS) are&#xD;
      useful alternative, but there is a need to improve their analgesic effect.Virtual reality&#xD;
      mirror therapy has shown the capacity to alleviate pain and may be easily coupled with&#xD;
      rTMS.The present project will investigate in individuals with neuropathic pain the effects of&#xD;
      the rTMS coupled with virtual reality mirror therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project introduces a new research question that incorporates virtual reality mirror&#xD;
      therapy into an established treatment protocol of repetitive transcranial magnetic&#xD;
      stimulation (rTMS) for neuropathic pain relief. Neuropathic pain is particularly difficult to&#xD;
      treat with classic first-line drugs. Neuromodulation techniques using repetitive transcranial&#xD;
      magnetic stimulation (rTMS) are useful alternative, but there is a need to improve their&#xD;
      analgesic effect.&#xD;
&#xD;
      Virtual reality mirror therapy has shown the capacity to alleviate pain and may be easily&#xD;
      coupled with rTMS. The efficacy of using both techniques in neuropathic pain treatment is&#xD;
      unknown. The present project will investigate in individuals with neuropathic pain the&#xD;
      effects of the rTMS coupled with virtual reality mirror therapy on: 1) daily pain intensity&#xD;
      (i.e. analgesic efficacy); 2) other components of pain and the quality of life; 3) brain&#xD;
      activity.&#xD;
&#xD;
      It will be the first to provide insight into the efficacy of using together both non-invasive&#xD;
      technics of cortical neuromodulation to alleviate pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1: patient with 4 sessions of active mirror therapy followed by an rTMS stimulation session of the primary motor cortex (M1), Group 2: patient with 4 sessions of sham mirror therapy followed by rTMS of the primary motor cortex (M1).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The (motor) task performed by the patient during the sham control mirror therapy session is identical to that performed in active mirror therapy. The only difference is that in sham mirror therapy there is no optical illusion of movement of the affected hand.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity measurement</measure>
    <time_frame>Week 9</time_frame>
    <description>Averages of the daily visual analogue scale scores (min no pain max pain imaginable) measured during the first week (Week 1) and that measured during the week following the last session (week 9)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life after treatment</measure>
    <time_frame>week 12</time_frame>
    <description>EQ5D scale (min = 0 worst imaginable health condition and max = 100 best health condition imaginable) and Analgesic consumption of Appeal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous brain activity</measure>
    <time_frame>week 12</time_frame>
    <description>Functional MRI at rest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuropathic dimension</measure>
    <time_frame>Week 3, 5, 7, 9,12</time_frame>
    <description>overall score of the neuropathic pain symptoms inventory (NPSI) (min = 0 no neuropathic pain and max = 100 intensive neuropathic pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Week 3, 5, 7, 9,12</time_frame>
    <description>Nature and number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>rTMS active and active mirror-based therapy using virtual reality</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and active mirror-based therapy using virtual reality.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rTMS active and sham mirror-based therapy using virtual reality</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and sham mirror-based therapy using virtual reality.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Repetitive transcranial magnetic stimulation (rTMS)</intervention_name>
    <description>20 minutes of high frequency (20Hz) rTMS.</description>
    <arm_group_label>rTMS active and active mirror-based therapy using virtual reality</arm_group_label>
    <arm_group_label>rTMS active and sham mirror-based therapy using virtual reality</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mirror therapy using virtual reality</intervention_name>
    <description>active mirror-based therapy</description>
    <arm_group_label>rTMS active and active mirror-based therapy using virtual reality</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mirror therapy using sham mirror</intervention_name>
    <description>20 minutes of sham mirror-based therapy</description>
    <arm_group_label>rTMS active and sham mirror-based therapy using virtual reality</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical symptoms typical of neuropathic pain&#xD;
&#xD;
          -  Refractory to drug therapies&#xD;
&#xD;
          -  Lasting for at least 6 months, with a moderate to severe pain intensity (≥4/10 on&#xD;
             Visual Analog Scale, VAS) and a stable pain treatment since 1month at least&#xD;
&#xD;
          -  Having right to health benefits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ferromagnetic components and implanted microprocessors (i.e. cochlear implants)&#xD;
&#xD;
          -  Drug-resistant or active epilepsy, pacemaker, pregnancy, ongoing depression or&#xD;
             personality troubles, and ongoing opioid treatment.&#xD;
&#xD;
          -  Any other contraindications to MRI scanner (e.g., claustrophobia, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Peyron, MDPHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CENTRE HOSPITALIER DE SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roland Peyron, MDPHD</last_name>
    <phone>(0)477825684</phone>
    <phone_ext>+33</phone_ext>
    <email>roland.peyron@univ-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatrice DEYGAS, CRA</last_name>
    <email>beatrice.deygas@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Luis Garcia-Larrea, MD</last_name>
      <phone>0)472118866</phone>
      <phone_ext>+33</phone_ext>
      <email>luis-jose.garcia-larrea@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick MERTENS, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie ANDRE-OBADIA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis GARCIA- LARREA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Roland PEYRON, MD PHD</last_name>
      <phone>(0)477825684</phone>
      <phone_ext>+33</phone_ext>
      <email>roland.peyron@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Christelle Créac'h, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roland PEYRON, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transcranial magnetic stimulation</keyword>
  <keyword>virtual reality</keyword>
  <keyword>mirror therapy</keyword>
  <keyword>brain networks</keyword>
  <keyword>predictive model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

